FDA Approves Two Novel Oral Treatments for Gonorrhea Amid rising Drug Resistance
The U.S. Food and Drug Administration has authorized two new oral medications – Nuzolvence (zoliflodacin) and Blujepa (gepotidacin) – to combat uncomplicated urogenital gonorrhea, a common sexually transmitted infection. the approvals, announced on December 12, 2025, represent a notable step forward in addressing the growing challenge of antibiotic resistance in Neisseria gonorrhoeae, the bacterium that causes gonorrhea.
Addressing a Public Health Concern
Gonorrhea, if left untreated, can lead to serious health complications including widespread infection of the reproductive organs and infertility. Symptoms can include painful urination, genital discharge, and swelling. according to the FDA,uncomplicated urogenital gonorrhea is defined as a localized infection of the urethra or cervix that hasn’t spread. Historically, treatment involved a combination of an injection (ceftriaxone) and an oral medication (azithromycin), but recent guidelines have shifted towards single-dose ceftriaxone injections.
“These approvals mark a significant milestone for treatment options for patients with uncomplicated urogenital gonorrhea,” stated Adam Sherwat,M.D., director of the Office of infectious Diseases in the FDA’s Center for Drug Evaluation and Research (CDER). The emergence of drug-resistant strains has underscored the urgent need for alternative therapies.
Nuzolvence: A Comparable Option for Adults and Adolescents
Nuzolvence, a granule formulation designed to dissolve in water, is approved for adults and children 12 years and older weighing at least 77 pounds. Clinical trials involving 930 patients demonstrated comparable efficacy to the standard ceftriaxone treatment. Specifically,91% of patients treated with Nuzolvence achieved bacterial clearance 4 to 8 days post-treatment,compared to 96% in the standard treatment group.
However, labeling for Nuzolvence includes crucial safety precautions. Animal studies suggest potential risks of birth defects, pregnancy loss, or male fertility problems. The medication is also not recommended for individuals with known allergies or those taking certain interacting medications. Common side effects observed in trials included low white blood cell counts, headache, dizziness, nausea, and diarrhea.
Blujepa: A Critical Option for Limited Treatment Choices
Blujepa, an oral tablet, is indicated for patients 12 years and older weighing at least 99 pounds, particularly those with limited alternative treatment options. The FDA previously approved Blujepa in March 2025 for urinary tract infections. A study of 628 patients showed a 93% cure rate with Blujepa, compared to 91% with standard treatment, demonstrating comparable effectiveness.
The agency noted that Blujepa’s approval is based on limited clinical safety data, necessitating careful consideration for its use. potential side effects include diarrhea, nausea, stomach pain, vomiting, gas, dizziness, soft stools, headache, tiredness, and excessive sweating.Moreover, Blujepa carries warnings related to potential effects on heart rhythm, brain chemicals, and the possibility of allergic reactions, including QTc prolongation and acetylcholinesterase inhibition.
“The availability of additional treatment options is of particular importance given the global rise in gonococcal drug resistance,” explained Peter Kim, M.D., M.S., director of the CDER Division of Anti-infectives.
Both nuzolvence and Blujepa received Fast track, Qualified Infectious Disease Product, and Priority Review designations from the FDA, expediting their development and review process. Entasis Therapeutics received approval for Nuzolvence, while GSK secured approval for Blujepa.
The FDA’s actions underscore the agency’s commitment to protecting public health by ensuring access to safe and effective treatments for infectious diseases, particularly in the face of evolving antimicrobial resistance.
